BioNTech SE (BNTX)

123.60 -4.60 (-3.59%) At close: 04:00PM EDT

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4,000

Key executives

Name	Title	Pay	Exercised	Year born
Prof. Ugur Sahin M.D.	Co-Founder, CEO & Chair of the Management Board	732.03k	N/A	1965
Dr. Ozlem Tureci M.D.	Co-Founder, Chief Medical Officer & Member of Management Board	725.56k	N/A	1967
Prof. Christoph Hubert Huber M.D., Ph.D.	Co-Founder & Member of Supervisory Board	63.61k	N/A	1944
Mr. Jens H. Holstein	CFO & Member of Management Board	877.57k	N/A	1963
Dr. Sierk Poetting Ph.D.	MD, COO & Member of Management Board	768.68k	N/A	1973
Mr. Ryan Richardson	Chief Strategy Officer, MD & Member of Management Board	664.11k	N/A	1979
Mr. Sean Marett	Chief Bus. Officer, Chief Commercial Officer & Member of Management Board	830.14k	N/A	1965
Sylke Maas Ph.D.	VP of Investor Relations and Bus. Strategy	N/A	N/A	N/A
Dr. James Timothy Patrick Ryan Ph.D.	Sr. VP & Gen. Counsel	N/A	N/A	N/A
Michael Boehler	MD & Head of Global External Communications	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Corporate governance

BioNTech SE’s ISS governance QualityScore as of 1 March 2023 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.